Man Group plc Buys Shares of 456,761 Exelixis, Inc. $EXEL

Posted by Brian Himes on Aug 27th, 2026

Man Group plc purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 456,761 shares of the biotechnology company’s stock, valued at approximately $24,852,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Motiv8 Investments LLC bought a new stake in Exelixis in the 4th quarter valued at about $26,000. Cassaday & Co Wealth Management LLC purchased a new stake in Exelixis during the first quarter valued at about $27,000. Western Wealth Management LLC bought a new position in Exelixis during the first quarter worth about $29,000. Acumen Wealth Advisors LLC purchased a new position in shares of Exelixis in the fourth quarter worth about $29,000. Finally, Activest Wealth Management purchased a new position in shares of Exelixis in the fourth quarter worth about $32,000. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on EXEL. Leerink Partners cut shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 price target on the stock. in a research note on Thursday, August 6th. Barclays lifted their price objective on shares of Exelixis from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 14th. Zacks Research cut shares of Exelixis from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. Truist Financial dropped their target price on Exelixis from $56.00 to $52.00 and set a “hold” rating on the stock in a research report on Thursday, August 6th. Finally, Stifel Nicolaus raised their price target on Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $50.07.

View Our Latest Report on EXEL

Exelixis Trading Down 1.1%

Shares of Exelixis stock opened at $56.10 on Thursday. The company’s 50-day moving average price is $54.46 and its 200-day moving average price is $48.88. Exelixis, Inc. has a 12-month low of $33.76 and a 12-month high of $57.57. The company has a market cap of $13.90 billion, a price-to-earnings ratio of 17.64, a PEG ratio of 1.69 and a beta of 0.44.

Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.85 by $0.06. The company had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. Exelixis’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.75 earnings per share. On average, sell-side analysts predict that Exelixis, Inc. will post 3.18 earnings per share for the current year.

Insiders Place Their Bets

In other Exelixis news, Director Mary C. Beckerle sold 9,812 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares of the company’s stock, valued at $862,799.14. This trade represents a 37.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sue Gail Eckhardt sold 9,812 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $50.14, for a total transaction of $491,973.68. Following the transaction, the director owned 16,079 shares of the company’s stock, valued at $806,201.06. This trade represents a 37.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,549 shares of company stock worth $1,216,894 in the last three months. 2.60% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

(Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.